Overview

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

Status:
Terminated

Trial end date:
2011-12-28

Target enrollment:

Participant gender:

Summary

This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Inc